London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed. Among 65 ...

Behind the Headlines is a bi-weekly panel discussion examining the latest trends, readouts, and other factors that drive pharmaceutical news and innovation. Each episode features consultants, venture ...

The market will be watching several catalysts in the second half of 2025, including U.S. approval for Blenrep and Phase 3 data for camlipixant in chronic cough. GSK also expects a regulatory decision ...

Developed by Boston Pharmaceuticals, efimosfermin is a fibroblast growth factor 21 (FGF21) analog currently in midstage clinical trials for steatotic liver disease, including metabolic dysfunction ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD).

BAYRY Reports Q1 Earnings Decline, Cuts Sales Guidance for 2025 Bayer’s first-quarter core earnings of €2.49 per share declined 11.7% year over year. Sales of €13.74 billion decreased0.1% on ...

Efimosfermin is an investigational long-acting variant of FGF21 protein designed to treat and prevent the progression of steatotic liver disease (SLD), commonly known as fatty liver disease.